| Symbol | ORMP |
|---|---|
| Name | ORAMED PHARMACEUTICALS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | BIOMED |
| Address | 1185 AVENUE OF THE AMERICAS,SUITE 228, THIRD FLOOR, NEW YORK, New York, 10036, United States |
| Telephone | 02-5660001 |
| Fax | 02-5660004 |
| office@oramed.com | |
| Website | www.oramed.com |
| Incorporation | USA - Delaware |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001176309 |
| Description | Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. Additional info from NASDAQ: |
New Form NT 10-Q - ORAMED PHARMACEUTICALS INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001213900-26-057722 <b>Size:</b> 21 KB
Read moreNew Form SCHEDULE 13G - ORAMED PHARMACEUTICALS INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001493152-26-023496 <b>Size:</b> 7 KB
Read moreNew Form 3 - ORAMED PHARMACEUTICALS INC. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001213900-26-056839 <b>Size:</b> 10 KB
Read more(99% Neutral) ORAMED PHARMACEUTICALS INC. (ORMP) Announces Business Combination
Read moreDirector KIDRON NADAV 🔴 sold 100.0K shares of ORAMED PHARMACEUTICALS INC. (ORMP) Transaction Date: Mar 12, 2026 | Filing ID: 028291
Read more(99% Neutral) Oramed Pharmaceuticals Inc. (ORMP) Announces Business Combination
Read moreNew Form SCHEDULE 13G/A - ORAMED PHARMACEUTICALS INC. <b>Filed:</b> 2026-02-09 <b>AccNo:</b> 0001373604-26-000012 <b>Size:</b> 8 KB
Read moreHexter Joshua 🟡 adjusted position in 0 shares (1 derivative) of ORAMED PHARMACEUTICALS INC. (ORMP) Transaction Date: Jan 22, 2026 | Filing ID: 009477
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00867594 | Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients | Phase2 | Brittle Type I Diabetes Mellitus | Completed | 2008-07-01 | 2008-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| lipoic acid | DRUG | Phase PHASE2 | Diabetics | UNKNOWN | NCT01224353 |
| Budesonide dry powder inhaler | DRUG | Phase PHASE2 | Asthma | UNKNOWN | NCT01269437 |
| Rivastigmine | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| Donepezil | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| Comparator: Placebo | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| EVP-6124 (1.0 mg/day) | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| EVP-6124 (0.3 mg/day) | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| EVP-6124 (0.1 mg/day) | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00766363 |
| EVP-0962 | DRUG | Phase PHASE2 | Mild Cognitive Impairment | COMPLETED | NCT01661673 |
| EVP-6308 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02001389 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01487135 |
| Drug: EVP-6308 | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02037074 |
| Experimental: EVP-6124 | DRUG | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01984736 |
| Drug: EVP-6124 | DRUG | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT01969136 |
| Brief Supportive and Behavioral Treatment | BEHAVIORAL | Phase PHASE2 | Nicotine Dependence | TERMINATED | NCT01480232 |
| NRT Patch (Placebo) | DRUG | Phase PHASE2 | Nicotine Dependence | TERMINATED | NCT01480232 |
| NicoDerm Patch (Active) | DRUG | Phase PHASE2 | Nicotine Dependence | TERMINATED | NCT01480232 |
| Placebo Capsule | DRUG | Phase PHASE2 | Nicotine Dependence | TERMINATED | NCT01480232 |
| EVP-6124 | DRUG | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01073228 |
| OMP-336B11 | DRUG | Phase PHASE1 | Locally Advanced Malignant Neoplasm | TERMINATED | NCT03295942 |
| Nivolumab | DRUG | Phase PHASE1 | Locally Advanced Cancer | TERMINATED | NCT03119428 |
| OMP-313M32 | DRUG | Phase PHASE1 | Locally Advanced Cancer | TERMINATED | NCT03119428 |
| FOLFOX | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT03035253 |
| trifluridine/tipiracil | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT03031691 |
| brontictuzumab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT03031691 |
| Pembrolizumab | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT02722954 |
| FOLFIRI | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT03035253 |
| OMP-131R10 | DRUG | Phase PHASE1 | Advanced Relapsed Tumors | COMPLETED | NCT02482441 |
| OMP-305B83 | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT03035253 |
| OMP-54F28 with Sorafenib | DRUG | Phase PHASE1 | Hepatocellular Cancer | COMPLETED | NCT02069145 |
| OMP-54F28 | BIOLOGICAL | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01608867 |
| OMP-54F28, Paclitaxel and Carboplatin | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02092363 |
| demcizumab | DRUG | Phase PHASE2 | Nonsquamous Nonsmall Cell Neoplasm of Lung | COMPLETED | NCT02259582 |
| Carboplatin | DRUG | Phase PHASE2 | Nonsquamous Nonsmall Cell Neoplasm of Lung | COMPLETED | NCT02259582 |
| Pemetrexed | DRUG | Phase PHASE2 | Nonsquamous Nonsmall Cell Neoplasm of Lung | COMPLETED | NCT02259582 |
| OMP-54F28, Nab-Paclitaxel and Gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02050178 |
| Vantictumab | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02005315 |
| Vantictumab combined with paclitaxel | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT01973309 |
| vantictumab | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01957007 |
| Docetaxel | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01957007 |
| Taxol | DRUG | Phase PHASE1 | Primary Peritoneal Carcinoma | TERMINATED | NCT01952249 |
| Cisplatin or Carboplatin | DRUG | Phase PHASE1 | Stage IV Small Cell Lung Cancer | TERMINATED | NCT01859741 |
| Etoposide | DRUG | Phase PHASE1 | Stage IV Small Cell Lung Cancer | TERMINATED | NCT01859741 |
| OMP-52M51 | DRUG | Phase PHASE1 | Relapsed or Refractory Solid Tumors | COMPLETED | NCT01778439 |
| OMP-18R5 | BIOLOGICAL | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01345201 |
| OMP-21M18 | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT01189942 |
| gemcitabine | DRUG | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT02289898 |
| Abraxane® | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01189929 |
| Demcizumab | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT02722954 |
| Nab-Paclitaxel | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02005315 |
| Gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02005315 |
| OMP-59R5 | DRUG | Phase PHASE1 | Stage IV Small Cell Lung Cancer | TERMINATED | NCT01859741 |
| Glyburide | DRUG | Phase PHASE2 | Traumatic Brain Injury | COMPLETED | NCT01454154 |
| Glyburide for Injection | DRUG | Phase PHASE2 | Ischemic Stroke | COMPLETED | NCT01794182 |
| Placebo | OTHER | Phase PHASE2 | Diabetics | UNKNOWN | NCT01224353 |
| BIIB093 | DRUG | Phase PHASE3 | Brain Edema | TERMINATED | NCT02864953 |
| ORMD 0801 | DRUG | Phase PHASE2 | Brittle Type I Diabetes Mellitus | COMPLETED | NCT00867594 |